{"title":"PCSK9抑制剂治疗氯拉替尼诱导的高胆固醇血症一种解决非小细胞肺癌治疗新需求的新方法","authors":"John C Ashton","doi":"10.52768/2379-1039/2012","DOIUrl":null,"url":null,"abstract":"Lorlatinib is a third generation ALK inhibitor used in the treatment of non-small cell lung cancer. Lorlatinib invariably causes hypercholesteremia, though most patients respond to statin therapy.","PeriodicalId":294824,"journal":{"name":"Open Journal of Clinical and Medical Case Reports","volume":"62 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of lorlatinib induced hypercholesterolemia with PCSK9 inhibitors; A new solution to an emerging need in non-small cell lung cancer therapy\",\"authors\":\"John C Ashton\",\"doi\":\"10.52768/2379-1039/2012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lorlatinib is a third generation ALK inhibitor used in the treatment of non-small cell lung cancer. Lorlatinib invariably causes hypercholesteremia, though most patients respond to statin therapy.\",\"PeriodicalId\":294824,\"journal\":{\"name\":\"Open Journal of Clinical and Medical Case Reports\",\"volume\":\"62 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Journal of Clinical and Medical Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52768/2379-1039/2012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Journal of Clinical and Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52768/2379-1039/2012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Treatment of lorlatinib induced hypercholesterolemia with PCSK9 inhibitors; A new solution to an emerging need in non-small cell lung cancer therapy
Lorlatinib is a third generation ALK inhibitor used in the treatment of non-small cell lung cancer. Lorlatinib invariably causes hypercholesteremia, though most patients respond to statin therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
